Ciphergen Stockholders Approve SELDI Divestiture to Bio-Rad

Oct 29, 2006

NEW YORK (GenomeWeb News) — Ciphergen Biosystems’ shareholders have given the company the green light to sell its proteomics instrument business to Bio-Rad Laboratories.

Under the terms of the agreement, originally disclosed in August, Ciphergen will unload the hardware branch to Bio-Rad for about $20 million in cash and a $3 million equity investment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Mouse Fight

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Seeing the Interactions

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

This Week in Science

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

For Millions

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.

Featured White Papers

Lipid Removal With Reference Applications in Serum and Bile Proteomics

Albumin & IgG Removal Reference Applications

95-plex Immune Cell Phenotyping Assay

Oct

10

Featured Webinar

GenomeWeb/ABRF 2017 Webinar Series: Ask the Experts: Ensuring High-Quality Proteomic Studies with Core Lab Resources

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.

Main menu